List of Excipients in Branded Drug EZALLOR SPRINKLE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sun Pharmaceutical Industries Inc	EZALLOR SPRINKLE	rosuvastatin	47335-984	AMMONIA
Sun Pharmaceutical Industries Inc	EZALLOR SPRINKLE	rosuvastatin	47335-984	BUTYL ALCOHOL
Sun Pharmaceutical Industries Inc	EZALLOR SPRINKLE	rosuvastatin	47335-984	CELLULOSE, MICROCRYSTALLINE
Sun Pharmaceutical Industries Inc	EZALLOR SPRINKLE	rosuvastatin	47335-984	CROSPOVIDONE
Sun Pharmaceutical Industries Inc	EZALLOR SPRINKLE	rosuvastatin	47335-984	D&C RED NO. 28

EZALLOR SPRINKLE Excipient Strategy and Commercial Opportunities

Last updated: August 25, 2026

EZALLOR SPRINKLE is a differentiated rosuvastatin calcium dosage form built around administration flexibility rather than a new active ingredient. Its commercial value is concentrated in patients who have difficulty swallowing conventional tablets, including pediatric patients and adults with dysphagia. The strongest opportunities are authorized-generic positioning, pediatric lipid management, hospital and long-term-care supply, and reformulation of other poorly accepted oral products using a sprinkle-capsule platform.

What is EZALLOR SPRINKLE and why does its excipient system matter?

EZALLOR SPRINKLE contains rosuvastatin calcium in a hard capsule dosage form. The capsule can be opened and the contents sprinkled onto a small amount of applesauce for immediate administration without chewing the granules. The product is approved in 5 mg, 10 mg, 20 mg and 40 mg strengths. Pediatric use is relevant primarily for patients aged 8 years and older with heterozygous familial hypercholesterolemia, subject to the product labeling and clinical circumstances.[1]

The formulation separates the administration problem from the pharmacologic problem. Rosuvastatin is already widely available as a tablet and generic tablets are low-cost. EZALLOR SPRINKLE therefore depends on the value of:

• A swallowable or sprinkle-based presentation.
• Dose flexibility.
• Acceptability in pediatric and dysphagic populations.
• Preservation of rosuvastatin stability and dissolution.
• A formulation that can be manufactured at a cost materially below the branded price.

The excipient system must maintain pellet or granule integrity during storage, prevent dose segregation, control drug release, mask taste and permit reproducible dispersion on soft food.

What excipient functions are required for a rosuvastatin sprinkle formulation?

A commercial sprinkle product normally requires multiple functional excipient layers rather than a simple powder blend.

Core or drug-layer excipients

The drug layer must distribute a low-dose active ingredient uniformly across multiparticulate cores. Likely functional categories include:

Excipient function	Commercial purpose
Inert starter cores or carrier particles	Establish uniform particle size and improve drug loading
Microcrystalline cellulose	Provides structure and compressibility in drug-layer processing
Lactose or another water-soluble filler	Supports drug dispersion and dissolution
Hydroxypropyl cellulose or hypromellose	Binds rosuvastatin to the carrier surface
Povidone or related binder	Improves coating efficiency and content uniformity
Surfactant or wetting agent	Improves aqueous wetting and dissolution of the drug layer

The selected binder must balance adhesion with rapid release. Excessive binder concentration can generate dense agglomerates, slow dissolution and increase the risk that the patient perceives a gritty residue.

Protective or release-controlling coating

A coating system can protect the drug layer from moisture, reduce powdering and improve handling. It may also control the release profile. For rosuvastatin, a delayed-release or extended-release profile is not necessarily required for pharmacologic reasons, so a dense functional coating can add cost without creating a strong clinical benefit.

The commercial target is usually an immediate-release multiparticulate system with:

• Adequate mechanical strength.
• Low friability.
• Minimal dust generation.
• Rapid dispersion in the gastrointestinal tract.
• No requirement to chew.
• Acceptable stability under normal storage conditions.

Taste and mouthfeel excipients

Rosuvastatin calcium can produce an unpleasant taste when granules remain in the mouth. Taste management is therefore a central development issue. Candidate approaches include:

• Polymer film coating.
• Lipid or wax-based taste barriers.
• Ion-exchange or complexation systems.
• Sweeteners and flavors in the carrier vehicle.
• Particle-size control to reduce residence time and grittiness.

A coating that is too thick can delay dissolution. A coating that is too thin may fail during sprinkling, transport or oral administration. The optimal design depends on dissolution testing, sensory evaluation and robustness after mixing with applesauce.

Capsule-shell excipients

The capsule shell must protect the multiparticulate fill from moisture and support product identification. Gelatin is conventional, but hypromellose capsules may offer advantages where vegetarian positioning, lower moisture transfer or improved processing is commercially important.

Capsule-shell colorants and opacifiers also have practical value. Distinctive color coding can reduce medication errors among multiple rosuvastatin strengths.

What FDA regulatory status does EZALLOR SPRINKLE have?

EZALLOR SPRINKLE was approved by the FDA under NDA 210591 on February 28, 2018, as a rosuvastatin calcium sprinkle capsule.[2] The product is a small-molecule drug, not a biologic. Biosimilar substitution and biosimilar litigation are therefore not relevant.

The main regulatory differentiation is the dosage form. An ANDA applicant seeking to market a therapeutically equivalent product would need to address:

1. Pharmaceutical equivalence.
2. Bioequivalence to the reference listed drug.
3. Multiparticulate content uniformity.
4. Dissolution across relevant media.
5. Stability and moisture protection.
6. Labeling for administration on applesauce.
7. Capsule opening and sprinkle performance.

An alternative formulation could potentially pursue a 505(b)(2) pathway if it differs materially from the reference product and requires reliance on FDA findings for rosuvastatin. A conventional equivalent sprinkle capsule would generally be evaluated through the ANDA route, subject to FDA classification and the reference-product listing.

What patents protect EZALLOR SPRINKLE?

The active ingredient, rosuvastatin, is no longer the principal exclusivity barrier. The commercial protection for EZALLOR SPRINKLE would instead depend on formulation, dosage-form, manufacturing and method-of-use rights, together with regulatory exclusivity and brand-market positioning.

Potentially relevant claim categories include:

• Multiparticulate rosuvastatin compositions.
• Drug-layered pellets or granules.
• Coatings that improve taste, stability or dissolution.
• Capsule contents suitable for sprinkling on soft food.
• Specific excipient ratios.
• Manufacturing processes for layering or coating rosuvastatin.
• Administration methods for patients unable to swallow tablets.

The FDA Orange Book is the controlling source for patents listed against the approved NDA. Listed patents can create an ANDA certification issue, including Paragraph IV challenges. A patent that is not listed may still support district-court litigation, but it may not create the same automatic regulatory stay associated with an Orange Book-listed patent.[3]

No biosimilar patent pathway applies. Generic entrants face a formulation and bioequivalence problem, not a biologic comparability problem.

When does EZALLOR SPRINKLE lose exclusivity?

The product’s exclusivity position differs from Crestor because EZALLOR SPRINKLE is a later dosage-form approval for an old active ingredient. It did not receive the commercial protection associated with a new molecular entity.

The relevant exclusivity categories are:

Exclusivity category	Relevance
New chemical entity exclusivity	Not available for rosuvastatin in the later sprinkle approval
Three-year new clinical investigation exclusivity	Potentially relevant to a new dosage form if qualifying clinical investigations supported approval
Pediatric exclusivity	Depends on the specific FDA award and applicable sponsor history
Orange Book patent term	Depends on the claims, filing dates and any patent-term adjustment
Formulation patents	May extend beyond active-ingredient patent expiry
Trade secrets	May protect coating composition, process parameters and scale-up know-how

The three-year exclusivity period, if awarded for the dosage-form approval, would not permanently block generic rosuvastatin tablets. It would be relevant only to applications relying on the protected dosage form or the underlying approval. Patent expiration dates must be assessed patent by patent rather than inferred from rosuvastatin’s older product history.

What generic entry risks exist for EZALLOR SPRINKLE?

Generic entry risk is material because rosuvastatin is a mature, high-volume statin with established raw-material suppliers, known pharmacology and extensive clinical data.

High-risk entry routes

A generic sponsor could pursue:

• A direct sprinkle-capsule ANDA.
• A capsule containing coated granules with a different excipient system.
• A powder or granule dosage form administered with soft food.
• A conventional tablet with a labeling strategy directed at swallowable patients.
• A 505(b)(2) product using a novel taste-masking or pediatric delivery system.

The most difficult technical issue is not rosuvastatin release alone. It is demonstrating that the multiparticulate product remains equivalent after the capsule is opened and administered with the labeled food vehicle.

Likely Paragraph IV issues

A Paragraph IV challenge could target claims covering:

• The sprinkle dosage form.
• Specific coating polymers.
• Stability under defined moisture conditions.
• Particle-size distributions.
• Drug-loading levels.
• Administration on applesauce.
• Manufacturing processes.

A weak patent estate would leave formulation patents vulnerable if claims depend on narrow excipient ranges that are easy to design around. Stronger protection would combine composition claims with process claims and performance limitations tied to dissolution, stability or taste-masking results.

How strong is the commercial patent estate for EZALLOR SPRINKLE?

The patent estate is likely less defensible than a novel-molecule estate because the product’s value is based on delivery and usability rather than new pharmacology. Its strength depends on claim breadth and whether competitors can reproduce the patient benefit with different excipients.

Stronger protection

Protection is stronger where claims cover:

• A broad multiparticulate architecture.
• Multiple coating materials.
• Defined performance outcomes.
• Capsule-opening and food-administration characteristics.
• Manufacturing steps that are difficult to avoid.
• Stability and dissolution requirements that correspond to the commercial product.

Weaker protection

Protection is weaker where claims are limited to:

• A single polymer.
• A narrow concentration range.
• Conventional fillers or binders.
• A single food vehicle.
• A process that can be replaced by fluid-bed coating, extrusion-spheronization or other standard technology.

Trade-secret protection can supplement patents for coating order, spray rate, inlet temperature, curing conditions and moisture-control specifications. Trade secrets do not prevent independent reverse engineering, but they can delay competitive scale-up.

What excipient strategy offers the best commercial opportunity?

The highest-value strategy is an immediate-release, taste-masked multiparticulate system with low manufacturing complexity.

Recommended development priorities

Priority	Development objective	Commercial rationale
1	Reduce bitterness and grittiness	Directly improves pediatric and dysphagia acceptance
2	Maintain rapid dissolution	Limits bioequivalence risk and avoids unnecessary release complexity
3	Use broadly available excipients	Reduces supply-chain and regulatory risk
4	Optimize low-dose uniformity	Critical for 5 mg strength and dose flexibility
5	Improve moisture protection	Supports shelf life and global distribution
6	Minimize coating weight gain	Reduces batch time and cost
7	Validate multiple soft-food vehicles	Expands prescribing and institutional use

A platform using standard pharmaceutical-grade polymers, microcrystalline cellulose, a soluble filler and a modest taste-masking layer would generally offer a better cost profile than a highly engineered lipid or nanotechnology system.

Which patient and market segments offer the clearest opportunity?

Pediatric dyslipidemia

Pediatric patients with familial hypercholesterolemia are the most obvious segment. A sprinkle product can improve administration where tablets are difficult to swallow and can support caregiver dosing. The opportunity is narrower than the adult statin market but has higher differentiation.

Adults with dysphagia

Potential users include older adults, patients with neurologic disease and patients in long-term-care settings. The product may reduce medication-administration friction, although reimbursement and formulary placement can limit uptake.

Hospital and specialty pharmacy

Hospitals and specialty pharmacies may value a product that can be administered without tablet swallowing. Packaging, unit-dose presentation and clear handling instructions are important purchasing factors.

International markets

Geographic expansion depends on local registration, food-vehicle labeling, capsule and excipient acceptability, and the availability of rosuvastatin generic alternatives. A sprinkle product may have greater differentiation in markets where pediatric lipid treatment is expanding and tablet competition is less aggressive.

How does EZALLOR SPRINKLE compare with conventional rosuvastatin tablets?

Attribute	EZALLOR SPRINKLE	Conventional rosuvastatin tablet
Active ingredient	Rosuvastatin calcium	Rosuvastatin calcium
Main differentiation	Sprinkle administration	Low-cost standard tablet
Pediatric usability	Higher for patients unable to swallow tablets	Lower
Manufacturing cost	Higher because of multiparticulate processing	Lower
Generic competition	More technically complex	Extensive
Taste risk	Requires coating or masking	Usually less exposed in intact tablet form
Dose strengths	5, 10, 20 and 40 mg	Broad generic availability
Patent value	Formulation and process dependent	Limited once active-ingredient protection expires
Commercial premium	Depends on swallowing and adherence benefit	Primarily price driven

Key Takeaways

• EZALLOR SPRINKLE’s value is its administration format, not rosuvastatin exclusivity.
• Excipient selection should prioritize taste masking, pellet integrity, rapid dissolution and low-dose uniformity.
• The most commercially attractive design is a conventional multiparticulate system using scalable coating and standard excipients.
• Pediatric familial hypercholesterolemia and adult dysphagia are the clearest differentiated markets.
• Generic risk is substantial because the active ingredient and clinical profile are well established.
• Formulation patents are most valuable when they cover performance and manufacturing features that are difficult to design around.
• Biosimilar risk is irrelevant because EZALLOR SPRINKLE is a small-molecule product.
• The FDA Orange Book, patent claims and any Paragraph IV litigation determine the practical timing of generic entry.[3]

FAQs

Can EZALLOR SPRINKLE be reformulated as a tablet?

Yes, but a tablet would generally remove the product’s principal differentiation. A more commercially defensible reformulation would preserve sprinkle administration while improving taste, stability or food compatibility.

Which excipients are most important for pediatric acceptance?

Taste-masking polymers, low-grit carriers, soluble fillers, sweeteners and flavor systems are the most important categories. Their suitability must be confirmed through dissolution, stability and sensory testing.

Is a liquid rosuvastatin formulation a direct substitute for EZALLOR SPRINKLE?

Not necessarily. A liquid formulation would introduce different stability, preservative, dosing-accuracy and palatability requirements and could require a separate regulatory strategy.

Can a competitor avoid EZALLOR SPRINKLE patents by changing the coating polymer?

Possibly. A polymer substitution may avoid a narrow composition claim, but it may not avoid broader claims covering multiparticulate structure, administration method, dissolution performance or manufacturing steps.

Does opening the capsule change rosuvastatin bioavailability?

The labeled sprinkle method is part of the approved product-use conditions. Any competing product that relies on capsule opening must demonstrate appropriate performance and bioequivalence under its proposed administration instructions.

References

1. U.S. Food and Drug Administration. (2024). EZALLOR SPRINKLE (rosuvastatin calcium) capsules: Prescribing information.
2. U.S. Food and Drug Administration. (2018). Drugs@FDA: EZALLOR SPRINKLE, NDA 210591.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.